3月7日，翰森制药宣布其首款减重药奥莱泊肽（HS-20094）Ⅲ期注册研究取得积极结果。该研究在中国33个临床中心开展，604例成年受试者参与，旨在评估奥莱泊肽对比安慰剂治疗48周的疗效与安全性。结果显示，奥莱泊肽组体重降幅显著，最高达19.3%，达成5%体重降幅的受试者比例最高达97.2%，且胃肠道耐受性优异，不良事件发生率及停药率更低。研究主要研究者纪立农教授评价其减重疗效显著，胃肠道耐受性...
Source Link3月7日，翰森制药宣布其首款减重药奥莱泊肽（HS-20094）Ⅲ期注册研究取得积极结果。该研究在中国33个临床中心开展，604例成年受试者参与，旨在评估奥莱泊肽对比安慰剂治疗48周的疗效与安全性。结果显示，奥莱泊肽组体重降幅显著，最高达19.3%，达成5%体重降幅的受试者比例最高达97.2%，且胃肠道耐受性优异，不良事件发生率及停药率更低。研究主要研究者纪立农教授评价其减重疗效显著，胃肠道耐受性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.